Ad
related to: AstraZeneca
Search results
3 No-Brainer Stocks to Buy in June
The Motley Fool via AOL· 6 days agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie (NYSE: ABBV), AstraZeneca< ...
AstraZeneca Gets Workers’ Covid-19 Faith Bias Suit Narrowed
Bloomberg Law· 1 day ago‘s bid to dismiss some claims from workers who asserted religious objections to its Covid-19 vaccination mandate proved successful when a federal court adopted a magistrate judge’s recommendations ...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 9 hours agoRecap of the Week’s Most Important Stories Lilly’s CFO Departs: Lilly’s executive vice president and...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 4 days agoAstrazeneca (AZN) closed the most recent trading day at $78.99, moving +1.24% from the previous...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
BMO maintains target on AstraZeneca shares, cites trial success By Investing.com
Investing.com· 2 days agoOn Wednesday, BMO Capital upheld its Outperform rating on AstraZeneca (NASDAQ:AZN) with a steady...
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 2 days agoFirst Trust Advisors LP grew its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% in the fourth quarter, according to its most recent filing with the Securities ...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 3 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 18 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Nucleus RadioPharma secures Series A investment from AstraZeneca
BioPharma-Reporter· 2 days agoThe investment from AstraZeneca marks a strategic move to further expand Nucleus's capabilities in developing targeted radiotherapies and theranostics, aimed at making cancer ...
